Endologix (ELGX) – Investment Analysts’ Weekly Ratings Updates
A number of firms have modified their ratings and price targets on shares of Endologix (NASDAQ: ELGX) recently:
- 10/9/2017 – Endologix had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $5.00 price target on the stock.
- 10/6/2017 – Endologix was given a new $6.00 price target on by analysts at Stifel Nicolaus. They now have a “hold” rating on the stock.
- 10/3/2017 – Endologix had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $5.00 price target on the stock.
- 9/27/2017 – Endologix had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $5.00 price target on the stock.
- 9/1/2017 – Endologix was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
Endologix, Inc. (ELGX) opened at 5.09 on Thursday. The company has a 50-day moving average price of $4.62 and a 200-day moving average price of $5.30. Endologix, Inc. has a 12-month low of $4.08 and a 12-month high of $13.17. The firm’s market cap is $424.68 million.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. The firm had revenue of $48.60 million during the quarter, compared to the consensus estimate of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The firm’s revenue was down 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.20) earnings per share. On average, equities analysts predict that Endologix, Inc. will post ($0.62) earnings per share for the current year.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc and related companies with MarketBeat.com's FREE daily email newsletter.